IP Library Granted Patent US 12,070,629
Granted Patent B2
US 12,070,629 · App. 17/340,334 · Granted Aug 27, 2024

Core stabilized microcapsules, method of their preparation and uses thereof

Inventors: Ofer Toledano (Kfar Saba, IL); Haim Bar-Simantov (Netanya, IL); Hanan Sertchook (Gedera, IL); Sharon Fireman-Shoresh (Tel-Aviv, IL); Dorit Marco (Rehovot, IL)
Assignee: Sol-Gel Technologies Ltd.
A61Q19/00A61K8/11A61K8/25A61K8/26A61K8/38A61K8/671A61K9/0014A61K9/06A61K9/10A61K9/501A61K9/5115A61K9/5192B01J13/14B01J13/18F28D20/023A61K9/5026A61K47/32A61K47/38A61K2800/412
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,070,629
App. No.
17/340,334
Granted
Aug 27, 2024
Kind
B2
Abstract

The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within an inorganic oxide shell, processes for their preparations, comparisons comprising them and uses thereof.

Claims (9)

1. A microcapsule comprising a core encapsulated by a metal oxide shell, wherein said core comprises at least one active agent, and at least one phase changing material; wherein the thickness of said metal oxide shell is in the range of 0.05-1 micron;

wherein said metal oxide shell is made from (a) metal oxide nanoparticles, and (b) a hydrolyzed and polymerized sol gel precursor; wherein said at least one active agent is in a solid form, and is a dermatological agent; wherein said at least one phase changing material is not liquid at room temperature; wherein said core has a viscosity of from about 300 cP to about 1,000,000 cP.

2. The microcapsule according to claim 1 , wherein said at least one phase changing material is selected from the group consisting of natural or synthetic paraffin, waxes, aliphatic alcohols, fatty acids, and any combination thereof, wherein said fatty acids have a formula of CH3(CH2)nCOOH, and wherein n=10-100.

3. The microcapsule of claim 1 , wherein said dermatological agent is selected from the group consisting of anti-fungal agents, anti-bacterial agents, anti-inflammatory agents, anti-pruritic agents, anti-psoriatic agents, anti-acne agents, anti-rosacea agents, and any combinations thereof.

4. The microcapsule of claim 3 , wherein said anti-acne agent is selected from the group consisting of benzoyl peroxide or a retinoid.

5. The microcapsule according to claim 1 , wherein said microcapsule is stable for a period of between about 2 weeks to about 2 years at room temperature.

6. A composition comprising the microcapsule of claim 1 .

7. The composition of claim 6 , wherein said composition is a pharmaceutical composition and further comprises at least one pharmaceutical acceptable carrier or excipient.

8. A method for treating a skin disease, disorder or condition in a subject in need thereof, said method comprising topically administering to said subject a composition according to claim 7 , wherein said at least one active agent is benzoyl peroxide or a retinoid, wherein said benzoyl peroxide or retinoid is in a solid form; and wherein said skin disease, disorder or condition is selected from the group consisting of acne, psoriasis, seborrhea, contact dermatitis, rosacea, and a combination thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2025
From: SOL-GEL TECHNOLOGIES LTD.
To: MAYNE PHARMA LLC
Reel/Frame 071148/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2021
From: TOLEDANO, OFER; BAR-SIMANTOV, HAIM; SERTCHOOK, HANAN; FIREMAN-SHORESH, SHARON; MARCO, DORIT
To: SOL-GEL TECHNOLOGIES LTD.
Reel/Frame 056461/0979 →
Continuity (5)
Continuation 15924331 · Mar 19, 2018
Continuation In Part 15834805 · Dec 7, 2017
Division 13500937
Provisional Application 61291594 · Dec 31, 2009
Related Publication 20210290985A1 · Sep 23, 2021